Literature DB >> 20352440

Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Ryusaburo Mori1, Mitsuko Yuzawa, Zeon Lee, Miho Haruyama, Eriko Akaza.   

Abstract

BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is considered to be a good indication for photodynamic therapy (PDT). We evaluated pre-PDT factors predicting better visual acuity (VA) 1 year after PDT in patients with PCV.
METHODS: We evaluated 181 eyes of 181 patients who underwent PDT and were followed up for 1 year. Additional treatments, if needed, were given every 3 months, with a maximum of four PDT sessions, for up to 9 months. We compared best-corrected VA (BCVA) 1 year after PDT with that before PDT. Pre-PDT factors favoring better BCVA 1 year after PDT were evaluated using stepwise multiple regression analysis.
RESULTS: Mean BCVA improved from 0.29 +/- 0.15 before PDT to 0.43 +/- 0.32 1 year after PDT (p < 0.001). BCVA improved in 55 eyes (30.4%), and was maintained in 110 (60.8%). Pre-PDT factors predicting better BCVA at 1 year were better initial BCVA (beta = 0.271, p < 0.001) within our eligibility criteria up to 0.6, a relatively small diameter of a network of vessels plus polypoidal lesions on indocyanine green angiography (beta = 0.249, p < 0.001), and the absence of a polypoidal lesion under the fovea (beta = 0.175, p = 0.011).
CONCLUSION: Better BCVA can be expected 1 year after PDT in eyes with PCV showing better initial BCVA, relatively small lesions on indocyanine green angiography, and no subfoveal polypoidal lesion before PDT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352440     DOI: 10.1007/s00417-010-1365-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  26 in total

1.  Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Yumiko Kurashige; Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2008-07-09       Impact factor: 5.258

2.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

3.  Polypoidal choroidal vasculopathy: natural history.

Authors:  Masanobu Uyama; Mitsumasa Wada; Yoshimi Nagai; Takashi Matsubara; Hiroshi Matsunaga; Ichiro Fukushima; Kanji Takahashi; Miyo Matsumura
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

4.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

5.  Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Yumiko Ojima; Akitaka Tsujikawa; Atsushi Otani; Yasuhiko Hirami; Hiroko Aikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2006-05       Impact factor: 5.258

6.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

7.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroko Aikawa; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2007-04-30       Impact factor: 5.258

8.  Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy.

Authors:  J Reche-Frutos; C Calvo-Gonzalez; J Donate-Lopez; J Garcia-Feijoo; M Leila; J Garcia-Sanchez
Journal:  Eur J Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 2.597

9.  Chorioretinal anastomosis after photodynamic therapy for polypoidal choroidal vasculopathy: CRA after PDT for PCV.

Authors:  Yuko Yodoi; Akitaka Tsujikawa; Atsushi Otani; Hiroko Aikawa; Nagahisa Yoshimura
Journal:  Int Ophthalmol       Date:  2007-08-15       Impact factor: 2.031

10.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

View more
  9 in total

1.  Photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Jay Kumar Chhablani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-06       Impact factor: 3.117

2.  Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.

Authors:  M Ho; E C F Lo; A L Young; D T L Liu
Journal:  Eye (Lond)       Date:  2014-09-26       Impact factor: 3.775

3.  Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Authors:  Mitsuhiro Imasawa; Yoichi Sakurada; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2011-05-11       Impact factor: 2.447

4.  Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.

Authors:  Wataru Kikushima; Yoichi Sakurada; Atsushi Sugiyama; Seigo Yoneyama; Naohiko Tanabe; Mio Matsubara; Fumihiko Mabuchi; Hiroyuki Iijima
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

5.  Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy.

Authors:  I-Hsin Ma; Yun Hsia; Yi-Ting Hsieh; Tzyy-Chang Ho; Tso-Ting Lai; Chung-May Yang; Chang-Hao Yang
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

6.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

7.  Baseline Optical Coherence Tomography Parameters That May Influence 6 Months Treatment Outcome of Polypoidal Choroidal Vasculopathy Eyes with Combination Therapy: A Short-Term Pilot Study.

Authors:  Rituparna Ghoshal; Sharanjeet Sharanjeet-Kaur; Norliza Mohamad Fadzil; Somnath Ghosh; NorFariza Ngah; Roslin Azni Abd Aziz
Journal:  Int J Environ Res Public Health       Date:  2021-05-18       Impact factor: 3.390

Review 8.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10

9.  Systemic steroids as an aid to the management of Idiopathic Polypoidal Choroidal Vasculopathy (IPCV): A descriptive analysis.

Authors:  Aditya Sudhalkar; Divya Balakrishnan; Subhadra Jalali; Raja Narayanan
Journal:  Saudi J Ophthalmol       Date:  2015-08-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.